腹膜透析的现状
本文综述腹膜透析(PD)的技术创新、政策推动及全球应用扩展,指出PD患者生存率已与中心血液透析相当,心血管事件占PD死亡近半,腹膜炎干预取得进展但各中心应用不均,并强调腹膜溶质水转运机制与长期PD腹膜结构功能改变为新干预靶点。
要点
- PD技术创新显著减少治疗相关并发症,患者维持PD时间延长,生存率已与中心血液透析相当。
- 公共政策变化推动全球多地PD使用空前扩展。
- PD患者近半死亡由心血管事件导致,需识别模式特异性因素。
核心结论
- PD技术创新减少并发症并延长维持时间,生存率已与中心血液透析相当;政策变化推动全球PD扩展;腹膜转运机制与长期结构功能改变提供新靶点;腹膜炎干预进展显著但各中心应用不均。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- PD患者生存率现已与中心血液透析相当。
- 与血液透析一样,PD中近半死亡由心血管事件导致。
- 腹膜炎干预进展显著,但各中心获益不均,主要因研究知识临床应用不平等。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Technical innovations in peritoneal dialysis (PD), now used widely for the long-term treatment of ESRD, have significantly reduced therapy-related complications, allowing patients to be maintained on PD for longer periods. Indeed, the survival rate for patients treated with PD is now equivalent to that with in-center hemodialysis. In parallel, changes in public policy have spurred an unprecedented expansion in the use of PD in many parts of the world. Meanwhile, our improved understanding of the molecular mechanisms involved in solute and water transport across the peritoneum and of the pathobiology of structural and functional changes in the peritoneum with long-term PD has provided new targets for improving efficiency and for intervention. As with hemodialysis, almost half of all deaths on PD occur because of cardiovascular events, and there is great interest in identifying modality-specific factors contributing to these events. Notably, tremendous progress has been made in developing interventions that substantially reduce the risk of PD-related peritonitis. Yet the gains have been unequal among individual centers, primarily because of unequal clinical application of knowledge gained from research. The work to date has further highlighted the areas in need of innovation as we continue to strive to improve the health and outcomes of patients treated with PD.
引用
- Mehrotra R, Devuyst O, Davies SJ, et al. The Current State of Peritoneal Dialysis. J Am Soc Nephrol. 2016. PMID: 27339663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。